99Tcm-p-aminohippuric acid as a new renal agent

99Tcm-p-aminohippuric acid (99Tcm-PAH) is a new renal radiopharmaceutical prepared from a lyophilized kit by the addition of sodium pertechnetate (Na99TcmO4). Each vial contains PAH, the calcium trisodium salt of diethylenetriamine pentaacetic acid (CaNa3DTPA) and stannous chloride (SnCl2.2H2O) in an inert atmosphere. It is a stable radiopharmaceutical with high radiochemical purity (> 95%). Its protein binding is very similar to that of 131I-OIH, but it is hydrophilic in character. Animal studies using 99Tcm-PAH have indicated that it provides renal images of satisfactory quality with no external background. Despite its almost identical radiochemical purity and HPLC analysis results to 99Tcm-DTPA, 99Tcm-PAH is rapidly secreted by the kidneys in a manner consistent with tubular secretion, as confirmed by rat probenecid studies, whereas 99Tcm-DTPA is excreted by glomerular filtration. The pharmacokinetic parameters of 99Tcm-PAH (t1/2(alpha)) = 2.5 min, t1/2(beta) = 41.7 min, Cl = 5.22 ml.min-1, Kel = 5.1 x 10(-4) min-1) differ from those of 99Tcm-DTPA. Evaluation of 99Tcm-PAH in two human volunteers confirmed its good renal characteristics: rapid disappearance from the vascular system, high uptake in kidneys followed by its very fast elimination, and low residual activity 20 min after its intravenous administration.

Change of pharmacokinetic parameters of 131I-hippuran caused by heparin

The radiochemical purity of 131I-hippuran determined by radiochromatographic analysis using Whatman No 3 MM paper and a mixture of n-butanol, acetic acid and water as developer, was 97.3 +/- 1.2%. O-131IB acid and less than 1% of free 131I were separated from the preparation. No radioactivity which would correspond to O-131IB acid was observed on the radiochromatogram when 131I-hippuran was incubated with HSA and heparin. Protein binding of 131I-hippuran as a function of radiochemical purity, and HSA and heparin concentrations were determined by the method of equilibrium dialysis. No effect of radiochemical purity on protein binding of 131I-hippuran was observed, the value obtained being 1.3 +/- 0.1%. Higher HSA concentrations increased protein binding but decreased retention activity on the dialysing membrane. Heparin decreased protein binding of 131I-hippuran by 47%. The biological half-times of excretion of 131I-hippuran with heparin were 4 min for the fast phase and 107 min for the slow phase. The results of biodistribution in experimental animals showed increased localization of 131I-hippuran with heparin in the kidneys and liver during the first 15 min after injection.

Comparative quality control of 99mTc-Pyrophosphate and 99mTc-diphosphonate radiopharmaceuticals

The results of analysis of 99mTc-Pyrophosphate (99mPyP), taken as a representative of the group of compounds having an organic P-O-P bond, and of the three diphosphonate compounds: methylene diphosphonate (MDP), 2,3-dicarboxy propane diphosphonate (DPD) and ethane-1-hydroxy-1, 1-diphosphonate (EHDP), which differ in their chemical structure, are shown. Also, some physicochemical parameters such as chloroform-water apparent partition coefficient, the osmotic pressure and pH values in final preparations were studied. The radiochemical purity of these radiopharmaceuticals was determined by the two methods: Sephadex chromatography for separation of 99mTc-hydrolysate and TLC on silica gel with 85% methanol for the determination of free 99mTcO-4. The yield of labelling for both methods was over 90%. Also, pharmacokinetic parameters such as binding to the plasma proteins and to erythrocytes were determined. 99mTc-PyP binding to plasma proteins was higher than the binding of diphosphonate compounds. The quantitative distribution of preparations was determined in experimental animals.